Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 32 entries
View as:

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01485991 Org: User:
Start: 02/29/12 End: 04/30/14 Due: 04/30/15

An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01281839 Org: User:
Start: 02/28/11 End: 02/28/13 Due: 02/28/14

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Phase: N/A Priority: Normal
NCT ID: NCT02269917 Org: User:
Start: 03/31/15 End: 10/31/20 Due: 10/31/21

A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Phase: N/A Priority: Normal
NCT ID: NCT01323244 Org: User:
Start: 12/31/11 End: 03/31/15 Due: 03/31/16

A Study to Investigate the Effect of Steady-State TMC278 on the Pharmacokinetics of a Single Dose of Digoxin

Phase: N/A Priority: Normal
NCT ID: NCT01519128 Org: User:
Start: 01/31/12 End: 04/30/12 Due: 04/30/13

A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT01615614 Org: User:
Start: 04/30/12 End: 09/30/12 Due: 09/30/13

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT01422330 Org: User:
Start: 09/30/11 End: 11/30/13 Due: 11/30/14

A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients

Phase: N/A Priority: Normal
NCT ID: NCT01466790 Org: User:
Start: 01/31/12 End: 01/31/14 Due: 01/31/15

A Study to Compare the Bioavailability of JNJ-47910382 Formulated as a Tablet and as Suspension in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT01662661 Org: User:
Start: 07/31/12 End: 09/30/12 Due: 09/30/13

A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted Conditions

Phase: N/A Priority: Normal
NCT ID: NCT01619527 Org: User:
Start: 04/30/12 End: 08/31/12 Due: 08/31/13

An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.

Phase: N/A Priority: Normal
NCT ID: NCT02397395 Org: User:
Start: 05/31/15 End: 05/31/16 Due: 05/31/17

A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT01938625 Org: User:
Start: 12/12/13 End: 07/28/15 Due: 07/28/16

TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

Phase: N/A Priority: Normal
NCT ID: NCT00896051 Org: User:
Start: 08/31/09 End: 04/30/12 Due: 04/30/13

Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382

Phase: N/A Priority: Normal
NCT ID: NCT01651767 Org: User:
Start: 08/31/12 End: 06/30/13 Due: 06/30/14

A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male Patients

Phase: N/A Priority: Normal
NCT ID: NCT01707342 Org: User:
Start: 10/31/12 End: 11/30/12 Due: 11/30/13

An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT01725529 Org: User:
Start: 11/30/12 End: 11/30/14 Due: 11/30/15

A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT01586325 Org: User:
Start: 05/25/12 End: 04/21/14 Due: 04/21/15

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants

Phase: N/A Priority: Normal
NCT ID: NCT01290679 Org: User:
Start: 03/31/11 End: 02/28/13 Due: 02/28/14

A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435.

Phase: N/A Priority: Normal
NCT ID: NCT01571570 Org: User:
Start: 03/31/12 End: 05/31/12 Due: 05/31/13

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT01289782 Org: User:
Start: 02/28/11 End: 01/31/13 Due: 01/31/14

A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus

Phase: N/A Priority: Normal
NCT ID: NCT01724086 Org: User:
Start: 10/31/12 End: 12/31/14 Due: 12/31/15

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants

Phase: N/A Priority: Normal
NCT ID: NCT02064842 Org: User:
Start: 02/28/14 End: 04/30/14 Due: 04/30/15

A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT01567735 Org: User:
Start: 03/27/12 End: 03/20/14 Due: 03/20/15

Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir

Phase: N/A Priority: Normal
NCT ID: NCT01582035 Org: User:
Start: 04/30/12 End: 11/30/13 Due: 11/30/14

A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT01719614 Org: User:
Start: 10/31/12 End: 01/31/13 Due: 01/31/14